Idience Overview
- Founded
-
2019

- Status
-
Private
- Employees
-
14

- Latest Deal Type
-
Early Stage VC
- (Upcoming)
- Investors
-
6
Idience General Information
Description
Developer of oncology drugs intended to deliver breakthroughs that drive innovation and transform cancer treatment. The company's drug is a potent inhibitor that prevents the repair of DNA single-strand breaks (SSB) and promotes the conversion of SSB to double-stranded breaks (DSB), which ultimately leads to synthetic lethality in cancer cells, enabling cancer patients by targeting multiple solid tumors as monotherapy and for combination with other anti-cancer agents.
Contact Information
Website
www.idience.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 2, Baumoe-ro 27-gil
- Seocho-gu
- Seoul, 06752
- South Korea
+82 00-000-0000
Idience Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Early Stage VC | Upcoming | Clinical Trials - Phase 2 | ||||
1. Early Stage VC (Series B) | 01-Oct-2020 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 2 |
Idience Patents
Idience Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20220117961-A1 | Pharmaceutical composition comprising phthalazinone derivatives | Pending | 16-Oct-2020 | 0000000000 | |
US-20210323945-A1 | Crystalline forms of phthalazinone compound | Granted | 21-Apr-2020 | 0000000000 | |
US-11390608-B2 | Crystalline forms of phthalazinone compound | Active | 21-Apr-2020 | 0000000000 | |
US-20210323946-A1 | Process for preparing a phthalazinone derivative and intermediates thereof | Pending | 21-Apr-2020 | 0000000000 | |
US-9844550-B2 | Phtalazinone derivatives and manufacturing process thereof | Active | 13-Sep-2013 | A61K31/502 | 00 |
Idience Executive Team (6)
Idience Signals
Idience Investors (6)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
DAYLI Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Kiwoom Securities Company | Corporation | Minority | 000 0000 | 000000 0 | |
Mirae Asset Capital | Asset Manager | Minority | 000 0000 | 000000 0 | |
Seoul Investment Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
T.S. Investment | PE/Buyout | Minority | 000 0000 | 000000 0 |